Emerald Mutual Fund Advisers Trust Has $16.22 Million Stake in KalVista Pharmaceuticals, Inc. $KALV

Emerald Mutual Fund Advisers Trust reduced its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 5.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 805,762 shares of the specialty pharmaceutical company’s stock after selling 49,699 shares during the quarter. Emerald Mutual Fund Advisers Trust owned approximately 1.57% of KalVista Pharmaceuticals worth $16,220,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of KALV. BNP Paribas Financial Markets raised its stake in KalVista Pharmaceuticals by 47.0% during the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock worth $46,000 after buying an additional 1,292 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in KalVista Pharmaceuticals during the third quarter valued at $55,000. Truvestments Capital LLC boosted its position in KalVista Pharmaceuticals by 253.8% during the fourth quarter. Truvestments Capital LLC now owns 4,684 shares of the specialty pharmaceutical company’s stock valued at $76,000 after acquiring an additional 3,360 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in KalVista Pharmaceuticals by 816.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 8,059 shares of the specialty pharmaceutical company’s stock worth $91,000 after acquiring an additional 7,180 shares during the period. Finally, Cerro Pacific Wealth Advisors LLC acquired a new stake in KalVista Pharmaceuticals during the 4th quarter worth about $162,000.

KalVista Pharmaceuticals Stock Performance

NASDAQ:KALV opened at $27.00 on Tuesday. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -7.80 and a beta of -0.12. The firm has a fifty day simple moving average of $26.90 and a two-hundred day simple moving average of $20.54. KalVista Pharmaceuticals, Inc. has a 12 month low of $9.83 and a 12 month high of $27.00.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The business had revenue of $40.86 million for the quarter, compared to analysts’ expectations of $39.03 million. Analysts expect that KalVista Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

Insider Transactions at KalVista Pharmaceuticals

In related news, insider Nicole Sweeny sold 1,489 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total value of $39,875.42. Following the completion of the sale, the insider directly owned 59,291 shares of the company’s stock, valued at $1,587,812.98. The trade was a 2.45% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Brian Piekos sold 1,489 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total value of $39,875.42. Following the transaction, the chief financial officer directly owned 21,661 shares in the company, valued at approximately $580,081.58. This trade represents a 6.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 39,971 shares of company stock valued at $965,493. 4.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on KALV shares. Needham & Company LLC lowered KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 21st. Wall Street Zen raised KalVista Pharmaceuticals to a “hold” rating in a research note on Saturday, June 13th. Stifel Nicolaus lifted their target price on KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Finally, JonesTrading lowered KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 30th. Three equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $33.25.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.